Navigation Links
Prous Institute Presents Innovative Approach to Drug Discovery
Date:2/26/2009

BARCELONA, February 26 /PRNewswire/ -- Prous Institute for Biomedical Research today presented its strategies for drug discovery on its newly designed website (http://www.prousresearch.com). A large computational project with basic research support and broad disease coverage is being developed at Prous Institute under the broad-based Epistemic Drug Discovery(R) project.

President and C.E.O. of the Institute, Dr. J.R. Prous, explained that "We are committed to accelerating biomedical knowledge by the synchronization of powerful expert knowledge-based systems and basic research. This next-generation drug R&D force is expected to increase the efficiency and efficacy of core drug R&D processes, facilitating continuous innovation."

Two main drug discovery programs are being developed at the Institute. One is focused on the design, synthesis and biological evaluation of new small-molecule modulators of autophagy as therapeutic agents for cancer and neurodegeneration (Alzheimer's disease and Huntington's disease). Another program looks at target-driven drug discovery from natural sources, covering type 2 diabetes, psychological stress and asthma. The Institute's computational tools enable the in silico screening of thousands of natural products in a rapid, reliable and cost-effective manner, as well as the discovery of new targets and new uses for existing drugs.

J.R. Prous commented "our approach is bringing us closer to drug discovery, and the Institute expects to have several compounds in preclinical evaluation by the end of this year (2009)."

About Prous Institute for Biomedical Research

Prous Institute is a privately-held research-driven organization committed to the discovery and development of innovative therapies through the use of its powerful computational tools and the support of basic research. Prous Institute also fosters the development of prediction technologies used for regulatory and industry safety screening programs. Prous Institute receives several government grants and actively collaborates with academia and industry.

For more information, please contact Prous Institute: Xavier Mensa E-mail: info@prousresearch.com, Tel: +34-93-457-17-95, or visit http://www.prousresearch.com


'/>"/>
SOURCE Prous Institute for Biomedical Research, S.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
2. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
3. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
4. American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows
5. Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons
6. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
7. IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
8. National Cancer Institute: Battling Cancer and a Recession
9. The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates
10. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
11. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... MALDEN, MA (PRWEB) , ... ... ... the leader in Less Exposure Surgery (LES®) Technologies, announced today the next ... the PedFuse Pedicle Screw System platform). In contrast to the competition, SpineFrontier ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
Breaking Biology Technology:
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
Breaking Biology News(10 mins):